| Dr Thomas Mitchell, MD | |
|
3551 Roger Brooke Dr, Fort Sam Houston, TX 78234-4504 | |
| (210) 916-0439 | |
| Not Available |
| Full Name | Dr Thomas Mitchell |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 13 Years |
| Location | 3551 Roger Brooke Dr, Fort Sam Houston, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124314000 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 0101253518 (Virginia) | Secondary |
| 208600000X | Surgery | DR.0067852 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Joseph Medical Center | Tacoma, WA | Hospital |
| Tacoma General Allenmore Hospital | Tacoma, WA | Hospital |
| University Medical Center | Las vegas, NV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mcv Associated Physicians | 4385542117 | 1312 |
| Multicare Health System | 7719899897 | 1704 |
| Unlv Medicine | 4183991458 | 145 |
News Archive
Using a virus to purposely mutate genes that produce cancer-driving proteins could shed light on the resistance that inevitably develops to cancer drugs that target them, a new study led by UT Southwestern scientists suggests.
Phase II trial findings have ruled out a combination of erlotinib and everolimus for advanced non-small-cell lung cancer patients with progression after chemotherapy.
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.
Medical Research Council (MRC) scientists at the University of Leicester have made a new advance in understanding how the body fights certain types of cancer and other disease such as Lupus and rheumatoid arthritis.
Inter Press Service examines efforts by the U.N. High-Level Task Force for the International Conference on Population and Development to overcome stigma surrounding sexual and reproductive health in global discussions about population growth and development.
› Verified 4 days ago
| Entity Name | Mcv Associated Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710959457 PECOS PAC ID: 4385542117 Enrollment ID: O20031230000559 |
News Archive
Using a virus to purposely mutate genes that produce cancer-driving proteins could shed light on the resistance that inevitably develops to cancer drugs that target them, a new study led by UT Southwestern scientists suggests.
Phase II trial findings have ruled out a combination of erlotinib and everolimus for advanced non-small-cell lung cancer patients with progression after chemotherapy.
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.
Medical Research Council (MRC) scientists at the University of Leicester have made a new advance in understanding how the body fights certain types of cancer and other disease such as Lupus and rheumatoid arthritis.
Inter Press Service examines efforts by the U.N. High-Level Task Force for the International Conference on Population and Development to overcome stigma surrounding sexual and reproductive health in global discussions about population growth and development.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Thomas Mitchell, MD 3551 Roger Brooke Dr, Fort Sam Houston, TX 78234-4504 Ph: () - | Dr Thomas Mitchell, MD 3551 Roger Brooke Dr, Fort Sam Houston, TX 78234-4504 Ph: (210) 916-0439 |
News Archive
Using a virus to purposely mutate genes that produce cancer-driving proteins could shed light on the resistance that inevitably develops to cancer drugs that target them, a new study led by UT Southwestern scientists suggests.
Phase II trial findings have ruled out a combination of erlotinib and everolimus for advanced non-small-cell lung cancer patients with progression after chemotherapy.
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.
Medical Research Council (MRC) scientists at the University of Leicester have made a new advance in understanding how the body fights certain types of cancer and other disease such as Lupus and rheumatoid arthritis.
Inter Press Service examines efforts by the U.N. High-Level Task Force for the International Conference on Population and Development to overcome stigma surrounding sexual and reproductive health in global discussions about population growth and development.
› Verified 4 days ago
Dr. George Earl Peoples Jr., M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 3851 Roger Brooke Dr, Fort Sam Houston, TX 78234 Phone: 210-916-4235 Fax: 210-916-5102 | |
Dr. Jeremy Tyler Bolin, MD Surgery Medicare: Medicare Enrolled Practice Location: 3551 Roger Brooke Dr, Fort Sam Houston, TX 78234 Phone: 210-539-9582 | |
Dr. John Christopher Graybill, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 3551 Roger Brooke Dr Dept Of, Attention Program Coordinator, Fort Sam Houston, TX 78234 Phone: 210-916-5371 | |
Dr. Jordan Lane Guice, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 3551 Roger Brooke Dr, Fort Sam Houston, TX 78234 Phone: 210-539-9582 | |
Dr. Tommy Alan Brown Ii, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 3551 Roger Brooke Dr, Fort Sam Houston, TX 78234 Phone: 210-916-3400 | |
Dr. Pamela Christine Masella, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 3551 Roger Brooke Dr, Fort Sam Houston, TX 78234 Phone: 210-916-0393 | |
Dr. Jamie Rand, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 3551 Roger Brooke Dr, Fort Sam Houston, TX 78234 Phone: 210-539-9582 |